Abstract
Advances in immuno-oncology in the treatment of metastatic urothelial cancer have overturned current perspectives on the treatment of this type of tumor. The success of using Immune checkpoint inhibitors in metastatic urothelial cancer raised the question of effectiveness of immunotherapy added to standard first-line chemotherapy. This review presents data coming from actual studies examining chemotherapy and immunotherapy in urothelial cancer, or a combination of these methods. Ongoing and planned clinical studies should help identify the optimal sequencing, feasibility of combination, and best duration of treatment with checkpoint inhibitors in urothelial cancer.
Highlights
Advances in immuno-oncology in the treatment of metastatic urothelial cancer have overturned current perspectives on the treatment of this type of tumor
The success of using Immune checkpoint inhibitors in metastatic urothelial cancer raised the question of effectiveness of immunotherapy added to standard first-line chemotherapy
This review presents data coming from actual studies examining chemotherapy and immunotherapy in urothelial cancer, or a combination of these methods
Summary
Advances in immuno-oncology in the treatment of metastatic urothelial cancer have overturned current perspectives on the treatment of this type of tumor. В журнале Lancet Oncology были представлены результаты исследования III фазы KEYNOTE-361, в котором пациенты с местно-распространенным нерезектабельным или метастатическим уротелиальным раком были рандомизированы в группы комбинации пембролизумаба (ингибитор PD-1) с традиционной химиотерапией, монотерапии пембролизумабом и химиотерапии в целях сравнения эффективности и безопасности данных подходов [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
